E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Chronic Hand Eczema |
Eccema crónico de manos |
|
E.1.1.1 | Medical condition in easily understood language |
Hand Eczema |
Eccema de manos |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Skin and Connective Tissue Diseases [C17] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the long-term safety of an as-needed treatment with twice-daily applications of delgocitinib cream 20 mg/g. |
Evaluar la seguridad a largo plazo del tratamiento con delgocitinib crema 20 mg/g dos veces al día según sea necesario. |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the long-term efficacy of an as-needed treatment with twice-daily applications of delgocitinib cream 20 mg/g. |
Evaluar la eficacia a largo plazo del tratamiento con delgocitinib crema 20 mg/g dos veces al día según sea necesario. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Signed and dated informed consent has been obtained prior to any protocol related procedures. • The baseline visit in this extension trial must coincide with the Week 16 (end-of-treatment) visit in the parent trial. • Subjects must have met eligibility criteria at screening and baseline in the parent trial. • Subjects must have completed the treatment period in the parent trial (to be assessed at baseline visit in this extension trial). • Subjects must have complied with the clinical trial protocol in the parent trial to the satisfaction of the investigator. • A woman of childbearing potential must use an acceptable method of birth control throughout the trial up until the end-of-treatment/early termination visit. |
• Obtención del consentimiento informado firmado y fechado antes de realizar cualquier procedimiento relacionado con el protocolo. • La visita basal de este ensayo de extensión debe coincidir con la visita de la semana 16 (visita de fin del tratamiento) del ensayo original. • Los sujetos deben haber cumplido los criterios de selección en las visitas de selección y visita basal del ensayo original. • Los sujetos deben haber completado el período de tratamiento del ensayo original (para ser evaluados en la visita basal en este ensayo de extensión). • Haber cumplido con el protocolo del ensayo clínico original de manera satisfactoria a criterio del investigador. • Las mujeres en edad fértil deben utilizar un método anticonceptivo aceptable durante todo el ensayo hasta la visita de fin de tratamiento/terminación anticipada. |
|
E.4 | Principal exclusion criteria |
• Subjects who prematurely discontinued treatment with the investigational medicinal product (IMP) or initiated rescue medication in the parent trial. • Subjects who experienced any AE during participation in the parent trial, which precludes further treatment with delgocitinib cream 20 mg/g in the judgement of the investigator. • Any medical or psychiatric condition that could put the subject at undue risk by participating in the trial, or which, by the investigator's judgment, makes the subject inappropriate for the trial. • Current participation in any other interventional clinical trial, except for parent trials. |
• Sujetos que interrumpieron prematuramente el tratamiento con el producto en investigación (PEI) o iniciaron tratamiento con medicación de rescate durante el ensayo original. • Sujetos que experimentaron algún AA durante la participación en el ensayo original que impida la continuación del tratamiento con delgocitinib crema 20 mg/g a juicio del investigador. • Cualquier afección médica o psiquiátrica que pudiera suponer un riesgo indebido para el sujeto al participar en el ensayo, o que, a juicio del investigador, haga que el sujeto no sea apropiado para el ensayo. • Participación actual en cualquier otro ensayo clínico, excepto los ensayos originales. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Number of treatment-emergent AEs from baseline up to Week 38. |
Número de AA durante el tratamiento desde la visita basal hasta la semana 38 |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
• IGA-CHE score at each scheduled visit from baseline up to Week 36. • IGA-CHE score of 0 (clear) or 1 (almost clear) at each scheduled visit from baseline up to Week 36. • HECSI score at each scheduled visit from baseline up to Week 36. • HECSI-75 at each scheduled visit from baseline up to Week 36. • HECSI-90 at each scheduled visit from baseline up to Week 36. |
• Puntuación IGA-CHE1 en cada visita programada desde la visita basal hasta la semana 36. • Puntuación IGA-CHE de 0 (ausente) o 1 (casi ausente) en cada visita programada desde la visita basal hasta la semana 36. • Puntuación HECSI2 en cada visita programada desde la visita basal hasta la semana 36. • Puntuación HECSI-75 en cada visita programada desde la visita basal hasta la semana 36. • Puntuación HECSI-90 en cada visita programada desde la visita visita basal hasta la semana 36. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Timepoint for evaluation described in each endpoint. |
El momento de evaluación de las variables secundarias se describe en cada variable. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 7 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 81 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS |
Última visita del último paciente (LSLV) |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | 19 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 1 |
E.8.9.2 | In all countries concerned by the trial days | 2 |